PACAP Receptor Inhibitors
Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) is a pleiotropic neuropeptide belonging to the secretin/glucagon superfamily, widely distributed throughout the central and peripheral nervous systems, as well as in endocrine glands. PACAP exerts its biological effects by binding to three G protein-coupled receptors (GPCRs): PAC1, VPAC1, and VPAC2. The PAC1 receptor is highly selective for PACAP, while VPAC1 and VPAC2 also bind vasoactive intestinal peptide (VIP). Upon ligand binding, these receptors primarily activate adenylate cyclase, leading to an increase in intracellular cyclic AMP (cAMP) levels, and can also activate phospholipase C, resulting in increased inositol triphosphate (IP3) and diacylglycerol (DAG). PACAP signaling is involved in a diverse range of physiological functions, including neuroprotection, neurogenesis, stress responses, circadian rhythm regulation, and pain modulation, particularly nociceptive processing and vasodilation. Dysregulation of PACAP signaling has been implicated in several pathological conditions. Most notably, PACAP is recognized as a potent vasodilator and a key mediator in the pathophysiology of migraine. Elevated PACAP levels have been observed during migraine attacks, and exogenous PACAP infusion can trigger migraine-like headaches in susceptible individuals.
This makes PACAP Receptor inhibitors, particularly PAC1 selective antagonists, highly attractive targets for migraine prevention and acute treatment. Beyond migraine, PACAP signaling is also implicated in inflammatory pain, anxiety, depression, and certain neurodegenerative diseases, although in some contexts (e.g., neuroprotection), PACAP agonists might be beneficial, while inhibitors would be considered when PACAP's effects are detrimental. Currently, no PACAP Receptor inhibitors are approved for clinical use. However, significant research and development efforts are focused on PAC1 receptor antagonists for migraine. Several small molecule PAC1 antagonists have progressed into clinical trials, including compounds like AMG 307, MK-3207, and VSN-16. While some have shown promise in early phases, challenges related to efficacy, pharmacokinetics, or off-target effects have led to the discontinuation of others. Peptidic antagonists, such as PACAP6-38, have been invaluable research tools for elucidating PACAP's physiological roles but lack the pharmacokinetic properties suitable for therapeutic drug development due to their poor bioavailability and short half-life. Therefore, the focus remains on developing non-peptidic small molecule antagonists with improved drug-like properties, including brain penetrance for CNS indications.
Preclinical studies are also exploring the potential of PACAP receptor inhibitors in other pain conditions and inflammatory disorders. PACAP receptor inhibitors are primarily classified by their receptor selectivity (PAC1 selective vs. pan-VPAC/PAC antagonists) and chemical nature (peptidic vs. non-peptidic small molecules). A major challenge in developing PACAP receptor inhibitors is achieving high selectivity for PAC1 over VPAC1 and VPAC2, as VIP, which also binds to VPAC receptors, has widespread physiological effects, including cardiovascular and gastrointestinal actions. Non-selective inhibition could lead to unwanted side effects. For CNS indications like migraine, adequate brain penetration is also crucial. Potential toxicities, if selectivity is not achieved, could include cardiovascular effects (e.g., blood pressure changes) or gastrointestinal disturbances.
Combination therapy with other migraine treatments, such as triptans or CGRP inhibitors, could offer synergistic benefits. Research tools include PACAP6-38, cell lines expressing specific PACAP receptors, animal models of migraine (e.g., nitroglycerin-induced), and cAMP accumulation assays to measure receptor activity.
